Infectious complications of vascular anomalies treated with sirolimus: A systematic review.
infections
mTOR
serious adverse events
sirolimus
vascular anomalies
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
19
10
2023
received:
22
09
2023
accepted:
21
10
2023
medline:
24
11
2023
pubmed:
7
11
2023
entrez:
7
11
2023
Statut:
ppublish
Résumé
Initially developed as immunosuppressive agents, mammalian target of rapamycin (mTOR) inhibitors are currently used widely in the management of vascular malformations and tumors. The incidence of infectious complications in the vascular anomalies (VA) population is not well defined. The goal of this systematic review was to better define the types and severity of reported infectious complications in patients with VAs treated with mTOR inhibition. This was a systematic review conducted following PRISMA guidelines evaluating all research articles focused on infectious complications in patients with VAs treated with sirolimus or everolimus. Thirty articles including 1182 total patients and 316 infections (in 291 unique patients) were ultimately included. The majority of infections were viral upper respiratory (n = 137, 54%), followed by pneumonia (n = 53, 20%), and cutaneous infections (n = 20, 8%). There were six total infection-related fatalities, which all occurred in patients younger than 2 years. Two cases of Pneumocystis jirovecii pneumonia (PJP) were reported. These were infants with kaposiform hemangioendothelioma (KHE) who were also treated with steroids and did not receive PJP prophylaxis. Almost one-third (n = 96, 32%) of infectious complications were graded 3-4 according to Common Terminology Criteria for Adverse Events (CTCAE) criteria. Details of patient age, subtype of VA, and timing of infection were lacking from many reports. Most infectious complications reported in patients with VA on mTOR inhibitors were viral respiratory infections and non-severe. Bacteremia, infectious fatalities, and PJP are exceedingly rare. Future studies are needed to clarify the spectrum of infectious risks in VA patients and to provide guidance for infection prevention.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Initially developed as immunosuppressive agents, mammalian target of rapamycin (mTOR) inhibitors are currently used widely in the management of vascular malformations and tumors. The incidence of infectious complications in the vascular anomalies (VA) population is not well defined. The goal of this systematic review was to better define the types and severity of reported infectious complications in patients with VAs treated with mTOR inhibition.
METHODS
METHODS
This was a systematic review conducted following PRISMA guidelines evaluating all research articles focused on infectious complications in patients with VAs treated with sirolimus or everolimus. Thirty articles including 1182 total patients and 316 infections (in 291 unique patients) were ultimately included.
RESULTS
RESULTS
The majority of infections were viral upper respiratory (n = 137, 54%), followed by pneumonia (n = 53, 20%), and cutaneous infections (n = 20, 8%). There were six total infection-related fatalities, which all occurred in patients younger than 2 years. Two cases of Pneumocystis jirovecii pneumonia (PJP) were reported. These were infants with kaposiform hemangioendothelioma (KHE) who were also treated with steroids and did not receive PJP prophylaxis. Almost one-third (n = 96, 32%) of infectious complications were graded 3-4 according to Common Terminology Criteria for Adverse Events (CTCAE) criteria. Details of patient age, subtype of VA, and timing of infection were lacking from many reports.
CONCLUSIONS
CONCLUSIONS
Most infectious complications reported in patients with VA on mTOR inhibitors were viral respiratory infections and non-severe. Bacteremia, infectious fatalities, and PJP are exceedingly rare. Future studies are needed to clarify the spectrum of infectious risks in VA patients and to provide guidance for infection prevention.
Substances chimiques
Sirolimus
W36ZG6FT64
Immunosuppressive Agents
0
Everolimus
9HW64Q8G6G
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30758Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Wolfe AD. Pediatric vascular anomalies: opportunities in primary care. In: Kamat DM, Frei-Jones M, eds. Benign Hematologic Disorders in Children: A Clinical Guide. Springer International Publishing; 2021:453-486.
ISSVA. ISSVA classification of vascular anomalies. ISSVA; 2018. Accessed March 2, 2021. https://www.issva.org/classification
Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16(1):306.
Trenor CC, Adams DM, eds. Vascular Anomalies: A Guide for the Hematologist/Oncologist. Springer International Publishing; 2020.
Kerr AM, Haas SM. Parental uncertainty in illness: managing uncertainty surrounding an “orphan” illness. J Pediatr Nurs. 2014;29(5):393-400.
Kerr AM, Harrington NG, Scott AM. Communication and the appraisal of uncertainty: exploring parents' communication with credible authorities in the context of chronic childhood illness. Health Commun. 2017;34(2):201-211.
Kerr AM, Harrington NG, Scott AM. Uncertainty management and decision making: parents' experiences during their first visit to a multidisciplinary clinic for their child's vascular anomaly. J Pediatr Nurs. 2020;52:18-24.
Kerr AM, Thompson CM, Rubinsky V. Memorable messages parents of children with vascular birthmarks receive from others: implications for stigma and identity. Health Commun. 2020;35(6):685-695.
Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018-1024.
Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.
Ji Y, Chen S, Yang K, et al. A prospective multicenter study of sirolimus for complicated vascular anomalies. J Vasc Surg. 2021;74(5):1673-1681.e3.
Harbers VEM, Rongen G, van der Vleuten CJM, et al. Patients with congenital low-flow vascular malformation treated with low dose sirolimus. Adv Ther. 2021;38(6):3465-3482.
Maruani A, Tavernier E, Boccara O, et al. Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial. JAMA Dermatol. 2021;157(11):1289-1298.
Shimano KA, Eng W, Adams DM. How we approach the use of sirolimus and new agents: medical therapy to treat vascular anomalies. Pediatr Blood Cancer. 2022;69(Suppl 3):e29603.
Ricci KW, Iacobas I. How we approach the diagnosis and management of complex lymphatic anomalies. Pediatr Blood Cancer. 2021;69(Suppl 3):e28985.
Queisser A, Seront E, Boon LM, Vikkula M. Genetic basis and therapies for vascular anomalies. Circ Res. 2021;129(1):155-173.
O'Shea AE, Valdera FA, Ensley D, et al. Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention. Clin Immunol. 2022;245:109095.
Nozawa A, Ozeki M, Yasue S, et al. Immunologic effects of sirolimus in patients with vascular anomalies. J Pediatr Hematol Oncol. 2020;42(5):e355-e360.
Rossler J, Eulalia B, Victoria D, et al. Severe adverse events during sirolimus “off-label” therapy for vascular anomalies. Pediatr Blood Cancer. 2021;68(8):e28936.
Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.
Maruani A, Tavernier E, Boccara O. Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial. JAMA Dermatol. 2021;157(11):1289-1298.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240-243.
Otomi K, Yamada A, Kurogi J, Kamimura S, Moritake H. Pneumocystis pneumonia during everolimus therapy for Kasabach-Merritt phenomenon. Pediatr Int. 2023;65(1):e15593.
Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127-2133.
Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood. 2022;139(11):1619-1630.
Russell TB, Rinker EK, Dillingham CS, Givner LB, McLean TW. Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendothelioma. Pediatrics. 2018;141:S421-S424.
Mäkinen T, Boon LM, Vikkula M, Alitalo K. Lymphatic malformations: genetics, mechanisms and therapeutic strategies. Circ Res. 2021;129(1):136-154.
Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program. 2020;2020(1):319-327.
Malpica L, van Duin D, Moll S. Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders. Am J Hematol. 2019;94(12):1396-1412.
Navarro M, Allemang-Trivalle A, Leducq S, et al. Indication for a pneumocystis prophylaxis therapy in patients with vascular anomalies treated with PIK3/AKT/mTOR pathway inhibitors: experts’ opinion and systematic review from the literature. Dermatology. 2023:1-10. doi:10.1159/000533675
Wang Z, Yao W, Sun H, et al. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up. J Dermatol. 2019;46(11):956-961.
Wang Y, Kong L, Sun B, Cui J, Shen W. Sirolimus for kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in two infants. J Craniofac Surg. 2020;31(4):1074-1077.
Ying H, Qiao C, Yang X, Lin X. A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas. Pediatrics. 2018;141:S425-S429.
Sandbank S, Sandbank S, Molho-Pessach V, Farkas A, Barzilai A, Greenberger S. Oral and topical sirolimus for vascular anomalies: a multicentre study and review. Acta Derm Venereol. 2019;99(11):990-996.